開授課程

大學部

  上學期：分子生物學、臨床鏡檢學實習、普通生物學

  下學期︰臨床鏡檢學含實驗

碩士班

  上學期︰無

  下學期︰無

My Lab實驗室研究摘要

本實驗室近年來聚焦於缺氧誘導因子 HIF-1α如何重塑非編碼RNA(ncRNA)樣貌，進而重新程式化癌症中的基因表現與翻譯調控。以「非典型(noncanonical)RNA生物學」框架切入，我們發現三個以HIF 1α為核心、連結缺氧訊號與 ncRNA 恆定性的機制：(I) HIF-1α促進 Dicer 的自噬性降解，廣泛抑制腫瘤抑制型miRNA，增強轉移特徵(JCI, 2018)。(II) HIF-1α透過不依賴傳統轉錄功能(transcription independent)的路徑，隔離(sequester)DGCR8、破壞microprocessor蛋白複合體組裝，阻斷pri miRNA的加工(Nucleic Acids Research, 2024)。(III) HIF-1α將DGCR8重新導向RNA exosome複合體，驅動選擇性snoRNA降解，串連缺氧與 rRNA 修飾及翻譯重編程(Nucleic Acids Research, 2026)。另外，本實驗室亦致力於臨床可轉譯的 RNA 生物標記研發，用於治療反應與抗藥性預測(BJC, 2022；Translational Oncology, 2024)，並取得相關診斷/預後應用專利。

Research Field

RNA-binding protein

Post-translational regulation

Precision oncology

指導學生之特殊榮譽

1.  指導李婕寧博士後研究員榮獲TSSCR x TES x TSDB 三會聯合研討大會Oral Presentation Award (2025)

2.  指導王　敏大學生榮獲114年暑期研究優選獎 (2025)

3.  指導余雅筑大學生榮獲國立成功大學113年UR大專生專題研究成果海報展暨海報競賽-研究獎-生醫組第一名(傑出獎) (2024)

4.  指導余雅筑、莊芸晴大學生榮獲113年國家科學及技術委員會大專學生研究計畫獎助 (2024)

5.  指導余雅筑大學生榮獲112年暑期研究優秀獎 (2024)

6.  指導張艾欣大學生榮獲112年暑期研究優選獎 (2024)

7.  指導曾培雅碩士生榮獲生物醫學聯合學術年會細胞及分子生物學學會永信李天德醫藥基金會壁報論文獎 (2023)

8.  指導賴輝寰博士生榮獲柯林論文獎生物醫學領域博士論文獎(2019)

9.  指導賴輝寰博士生榮獲第28屆王民寧獎之「國內醫藥研究所博士班優秀論文獎」 (2018)

榮譽及獎勵

1.  Springer Nature 2025年度卓越編輯獎(Editor of Distinction Award, 2025)

2.  財團法人成杏醫學文教基金會優秀論文獎(2025)

3.  國家科學及技術委員會吳大猷先生紀念獎獎助計畫(2023-2026)

4.  國家科學及技術委員會111年度吳大猷先生紀念獎(2022)

5.  國家科學及技術委員會2030跨世代年輕學者方案-優秀年輕學者研究計畫獎助(2022-2025)

6.  國立成功大學110學年度教學特優(傑出)教師(2022)

7.  國立成功大學110學年度輔導優良導師(2022)

8.  科技部(現改制為國家科學及技術委員會)-優秀年輕學者研究計畫獎助(2014-2017)

 

Selected Publications Within Five Years (as a first/corresponding author)

1. Hui-Huang Lai, Jie-Ning Li, Ming-Yang Wang, Hsin-Yi Huang, Carlo M. Croce, Hui-Lung Sun, Yu-Jhen Lyu, Jui-Wen Kang, Ching-Feng Chiu, Mien-Chie Hung, Hiroshi I. Suzuki, Pai-Sheng Chen* (2018, Feb). HIF-1α promotes autophagic proteolysis of Dicer and enhances tumor metastasis. Journal of Clinical Investigation, 2018 Feb 1;128(2):625-643. doi: 10.1172/JCI89212. (IF 13.3, Ranking 2.1%) *Corresponding Author (指導第一作者賴輝寰博士生獲第28屆王民寧獎之「國內醫藥研究所博士班優秀論文獎」以及柯林論文獎生物醫學領域博士論文獎)

2. Hui-Huang Lai, Pai-Sheng Chen* (2018, Aug). Dual mechanism of Dicer downregulation facilitates cancer metastasis. Molecular & Cellular Oncology, 24;5(5):e1472056. doi: 10.1080/23723556.2018.1472056. eCollection 2018. (IF 2.6, Ranking 54.3%) *Corresponding Author

3. Hui-Huang Lai, Li-Jyuan Lin, Liang-Yi Hung and Pai-Sheng Chen* (2018, Nov). Role of Dicer in regulating oxaliplatin resistance of colon cancer cells. Biochemical and Biophysical Research Communications, 506:87-93. pii: S0006-291X(18)32227-7. doi: 10.1016/j.bbrc.2018.10.071. [Epub ahead of print]. MOST 107-2320-B-006-009. (IF 2.5, Ranking 69%) *Corresponding Author

4. Hui-Huang Lai, Chih-Wei Li, Chih-Chen Hong, Hung-Yu Sun, Da-Liang Ou, Pai-Sheng Chen* (2019, Jan). TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma. Molecular Oncology, 2019 Jan 18. doi: 10.1002/1878-0261.12449. [Epub ahead of print]. MOST 107-2320-B-006-068. (IF 5.0, Ranking 20.8%) *Corresponding Author

5. Ming-Yang Wang, Hsin-Yi Huang, Yao-Lung Kuo, Chiao Lo, Hung-Yu Sun, Yu-Jhen Lyu, Bo-Rong Chen, Jie-Ning Li, Pai-Sheng Chen*. (2019, Feb). TARBP2-Enhanced Resistance During Tamoxifen Treatment in Breast Cancer. Cancers, 2019, 11(2), 210; doi.org/10.3390/cancers11020210. European Patent Approved No. 3 539 541 (IF 4.5, Ranking 24.2%) *Corresponding Author

6. Pai-Sheng Chen#, Shao-Chieh Lin, Shaw-Jenq Tsai* (2020, Mar). Complexity in Regulating microRNA Biogenesis in Cancer. Experimental Biology and Medicine, 245(5):395-401. doi: 10.1177/1535370220907314. Epub 2020 Feb 19. (IF 2.8, Ranking 48.7%) #First Author

7. Pai-Sheng Chen#, Wen-Tai Chiu, Pei-Ling Hsu, Shih-Chieh Lin, I-Chen Peng, Chia-Yih Wang, Shaw-Jenq Tsai* (2020, May). Pathophysiological Implications of Hypoxia in Human Diseases. Journal of Biomedical Science, 27(1):63. doi: 10.1186/s12929-020-00658-7. (IF 9.0, Ranking 7.9%) #First Author

8. Jie-Ning Li, Hui-Lung Sun, Ming-Yang Wang, Pai-Sheng Chen* (2021, Jul). E-cadherin Interacts With Posttranslationally-Modified AGO2 to Enhance miRISC Activity. Frontiers in Cell and Developmental Biology, 9:671244. doi: 10.3389/fcell.2021.671244. eCollection 2021. (IF 4.6, Ranking 12.8%) *Corresponding Author

9. Jie-Ning Li, Ming-Yang Wang, Yi-Ting Chen, Yao-Lung Kuo, Pai-Sheng Chen* (2021, Dec). Expression of SnoRNA U50A Is Associated with Better Prognosis and Prolonged Mitosis in Breast Cancer. Cancers. 13(24):6304. doi: 10.3390/cancers13246304. European Patent Approved. (IF 4.9, Ranking 24.2%) *Corresponding Author

10. Yu-Yun Shao#, Pai-Sheng Chen#, Liang-In Lin, Bin-Shyun Lee, Andrew Ling, Ann-Lii Cheng, Chiun Hsu & Da-Liang Ou* (2022, Mar). Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma. British Journal of Cancer. doi: 10.1038/s41416-022-01759-w. Online ahead of print. (IF 8.1, Ranking 14.3%) #First Author

11. Jie-Ning Li, Zhu-Jun Loh, Hui-Wen Chen, I-Ying Lee, Jui-Hung Tsai*, Pai-Sheng Chen*. SnoRNA U50A mediates everolimus resistance in breast cancer through mTOR downregulation. Translational Oncology, Volume 48, 2024. (IF 4.5, Ranking 24.2%) *Corresponding Author 

12. Jie-Ning Li, Ming-Yang Wang, Yu-Jhen Lyu, Pownraj Brindangnanam, Mohane Selvaraj Coumar, Pai-Sheng Chen*. (2024, Aug). A transcription-independent role for HIF-1α in modulating microprocessor assembly. Nucleic Acids Research. Accepted. (IF 16.1, Ranking 1.9%) *Corresponding Author 

13. Pai-Sheng Chen#,* (2019, Feb). Regulation of Selective Proteolysis in Cancer. The Ubiquitin/Proteasome System. Matthew Summers, editor, IntechOpen, London, UNITED KINGDOM. ISBN 978-953-51-7766-1 (Invited book chapter) *Corresponding Author

 

Invited Talk

1.  A transcription-independent role for HIF-1α in modulating microprocessor assembly.第四屆台北表觀遺傳及染色質研討會暨台灣表觀遺傳學會2024年會 2024/09/19-20 (Invited speaker)

2.  全國醫檢生技教學調和研討會 2023/11/04

3.  A noncanonical HIF-1α pathway for metastasis control.第13屆海峽兩岸細胞生物學學術研討會 2018/07/18-22 (Invited speaker)

4.  Exoswitch: a rethink of HIF-1α. 成功大學醫學院教師研究討論會 2022/05/27 (Invited speaker)

 

Patents

1.  Method of Evaluating Drug Resistance and Treatment Effect. European Patent #EP3539541(granted in Germany, United Kingdom, and France),approved December 2020

發明人: Chen Pai-Sheng*, Li Jie-Ning, Kuo Yao-Lung, Wang Ming-Yang

所有人: National Cheng Kung University (本專利獲選成大優質專利)

2.  Method of Evaluating Drug Resistance and Treatment Effect. U.S. Patent #11,435,353 B2,approved September 2022

發明人: Chen Pai-Sheng*, Li Jie-Ning, Kuo Yao-Lung, Wang Ming-Yang

所有人: National Cheng Kung University (本專利獲選成大優質專利)

3.  Method and Kit for the Evaluation of the Prognosis of Breast Cancer European Patent #EP3540078,approved October 2022

發明人: Chen Pai-Sheng*, Li Jie-Ning, Kuo Yao-Lung

所有人: National Cheng Kung University (本專利獲選成大優質專利)

 

Experience/Service

1.  成大醫院乳房醫學中心研究顧問

2.  國科會計畫複審委員

3.  國科會計畫初審委員

4.  國科會大專生研究計畫審查委員

5.  國科會大專學生研究計畫創作獎審查委員

6.  國立臺灣大學高等教育深耕計畫─學術研究生涯發展研究計畫審查委員

7.  永信李天德醫藥科技論文獎審查委員

8.  經濟部工業局產業競爭力中心業界訪視服務專家

9.  成大醫學院教學優良及大學社會特優教師遴選委員

 

Society & Academic Service

1.  秘書長｜台灣表觀遺傳學會(Taiwan Epigenetics Society)

2.  理事｜台灣毒物學學會(Toxicology Society of Taiwan)

3.  終身會員｜台灣毒物學學會(Toxicology Society of Taiwan)

4.  會員｜中華民國癌症醫學會(Taiwan Oncology Society)

 

Editorial Leadership

1.  Breast Cancer Research (Associate Editor)

 

Invited SCI Journal Reviewer (Selected Journal list)

1.  Cancer Communications

2.  Journal of Advanced Research

3.  Cancer Research

4.  Oncogene

5.  Drug Resistance Updates

6.  Cancer Letters

7.  Journal of Biomedical Science

8.  Molecular Oncology

9.  Therapeutic Advances in Medical Oncology

10.  Oncogenesis

11.  European Journal of Pharmacology